Corvus Pharmaceuticals Inc. [CRVS] Begins COVID-19 Trail as Stock trades around $4.95 per share: What’s Next?

Corvus Pharmaceuticals Inc. [NASDAQ: CRVS] stock went on an upward path that rose over 80.84% on Tuesday, amounting to a one-week price increase of more than 72.65%. Yesterday, Corvus announced that it has started the Phase 1 study for investigating a novel immunotherapy approach for COVID-19 patients.

The first stage of the study was conducted at Temple University Hospital in Philadelphia, PA where a group of five patients went under the trail.  In the second stage of Phase 1 study, more than 30 patients will go through the trails expected to be held in different cities of the U.S. The results of the following investigational study will be observed by the U.S. Food and Drug Administration along with the acceptance of the investigational new drug (IND) application based on COVID-19 study.

Over the last 12 months, CRVS stock dropped by -16.86%. The average equity rating for CRVS stock is currently 1.60, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $141.22 million, with 29.41 million shares outstanding and 23.24 million shares in the current float. Compared to the average trading volume of 131.91K shares, CRVS stock reached a trading volume of 96895249 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Corvus Pharmaceuticals Inc. [CRVS]:

Mizuho have made an estimate for Corvus Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 12, 2019. While these analysts kept the previous recommendation, ROTH Capital raised their target price to Buy. The new note on the price target was released on May 29, 2019, representing the official price target for Corvus Pharmaceuticals Inc. stock.

The Average True Range (ATR) for Corvus Pharmaceuticals Inc. is set at 0.55 The Price to Book ratio for the last quarter was 2.43, with the Price to Cash per share for the same quarter was set at 2.41.

CRVS Stock Performance Analysis:

Corvus Pharmaceuticals Inc. [CRVS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 72.65. With this latest performance, CRVS shares gained by 51.07% in over the last four-week period, additionally plugging by 9.87% over the last 6 months – not to mention a drop of -16.86% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRVS stock in for the last two-week period is set at 76.47, with the RSI for the last a single of trading hit 83.82, and the three-weeks RSI is set at 70.86 for Corvus Pharmaceuticals Inc. [CRVS]. The present Moving Average for the last 50 days of trading for this stock 3.19, while it was recorded at 3.13 for the last single week of trading, and 3.49 for the last 200 days.

Insight into Corvus Pharmaceuticals Inc. Fundamentals:

Return on Total Capital for CRVS is now -52.92, given the latest momentum, and Return on Invested Capital for the company is -50.80. Return on Equity for this stock declined to -51.44, with Return on Assets sitting at -46.24. When it comes to the capital structure of this company, Corvus Pharmaceuticals Inc. [CRVS] has a Total Debt to Total Equity ratio set at 4.48. Additionally, CRVS Total Debt to Total Capital is recorded at 4.29, with Total Debt to Total Assets ending up at 3.81. Long-Term Debt to Equity for the company is recorded at 3.25, with the Long-Term Debt to Total Capital now at 3.11.

Reflecting on the efficiency of the workforce at the company, Corvus Pharmaceuticals Inc. [CRVS] managed to generate an average of -$880,604 per employee.Corvus Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.00 and a Current Ratio set at 6.00.


With the latest financial reports released by the company, Corvus Pharmaceuticals Inc. posted -0.44/share EPS, while the average EPS was predicted by analysts to be reported at -0.43/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -2.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CRVS.

Corvus Pharmaceuticals Inc. [CRVS] Insider Position Details

There are presently around $57 million, or 75.10% of CRVS stock, in the hands of institutional investors. The top three institutional holders of CRVS stocks are: ORBIMED ADVISORS LLC with ownership of 6,767,584, which is approximately 0% of the company’s market cap and around 10.50% of the total institutional ownership; ADAMS STREET PARTNERS LLC, holding 3,275,616 shares of the stock with an approximate value of $8.97 million in CRVS stocks shares; and NOVO HOLDINGS A/S, currently with $8.02 million in CRVS stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Corvus Pharmaceuticals Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 22 institutional holders increased their position in Corvus Pharmaceuticals Inc. [NASDAQ:CRVS] by around 988,188 shares. Additionally, 14 investors decreased positions by around 1,115,152 shares, while 12 investors held positions by with 18,549,593 shares. The mentioned changes placed institutional holdings at 20,652,933 shares, according to the latest SEC report filing. CRVS stock had 11 new institutional investments in for a total of 124,733 shares, while 5 institutional investors sold positions of 912,851 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam